Actively Recruiting
Determination of Pancreatic Steatosis Prevalence and Correlation With High-risk Cyst Features in Patients With Pre-malignant Pancreatic Cystic Neoplasms Using Magnetic Resonance Imaging and Endoscopic Ultrasound
Led by Chinese University of Hong Kong · Updated on 2025-08-11
236
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Pancreatic cancer is a leading cause of cancer deaths globally and in Hong Kong, with a very high fatality rate. Diagnosing it early is challenging due to the pancreas's deep location, which delays treatment and worsens survival. This research focuses on improving pancreatic cancer prevention and early detection, especially by identifying risk factors and monitoring pre-malignant pancreatic cystic lesions in high-risk patients using imaging techniques like MRI and endoscopic ultrasound (EUS). The study compares two groups: patients with at least one pancreatic cystic lesion presumed to be intraductal papillary mucinous neoplasm (IPMN) or mucinous cystic neoplasm (MCN) of size 5 mm or larger, and healthy subjects without such cysts. Participants undergo specialized MRI scans to measure pancreatic and liver fat content using advanced imaging sequences. This helps determine the prevalence of pancreatic steatosis and its possible link with cyst features that indicate higher cancer risk. Participants are involved in a one-time MRI procedure to quantify fat content in the pancreas and liver. Researchers analyze the prevalence of pancreatic steatosis, examine cyst features using EUS, and investigate risk factors associated with pancreatic steatosis. The study aims to refine risk assessment for pancreatic cyst progression and cancer development by adding information about pancreatic fat. Participation includes providing consent and completing the imaging procedures, with the study expected to end in April 2026.
CONDITIONS
Brief Title
Determination of Pancreatic Steatosis Prevalence and Correlation With High-risk Cyst Features
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 or older
- Patients with at least 1 pancreatic cystic lesion presumed to be IPMN or MCN based on CT, MRI or EUS features, with a cyst size 65 5mm; or healthy subjects
- Ability to provide written informed consent and comply with study procedures
You will not qualify if you...
- Unable to provide written informed consent
- Presence of metallic implants or other contraindications to MRI
- Contraindications for endoscopy due to other health conditions
- Known pancreatic cancer or prior pancreatic surgery
- Significant alcohol consumption exceeding 20 g daily for men or 10 g daily for women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - At the time of procedure
Participants undergo MRI to quantify pancreatic and liver fat, and endoscopic ultrasound to assess pancreatic cystic lesions and identify high-risk features.
1 visit (in-person)
Trial Site Locations
Total: 1 location
1
Prince of Wales Hospital, The Chinese University of Hong Kong
Shatin, New Territories, Hong Kong
Actively Recruiting
Research Team
F
Felix Sia
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here